CA-CROQUET-CORPORATION
The world’s perception of what real-time collaboration can actually look like is about to change. Croquet Corporation , the technology leader in Edge Collaboration (a new, rapidly-growing sector of Edge Computing) has launched the Croquet Collaboration Platform™ allowing developers worldwide to create multi-user apps with real-time capabilities never before possible.
While Croquet’s exclusive mission is delivering developer tools and infrastructure – including the Croquet Library , APIs and highly useful frameworks – the company has launched a free reference app called PiiX (Photo Instantaneous Interactive Experience) to showcase the technology. PiiX allows anyone, from consumers to sophisticated developers, to test-drive this revolutionary new collaboration technology right now, with no registration required.
Scan a QR code and watch as PiiX, a real-time, collaborative annotation app jumps instantly onto your phone or tablet. Invite others and as you annotate or manipulate the image, the results appear simultaneously in real-time on all participant screens. All users have simultaneous control. Users often describe the experience as “magical”. But it’s the global infrastructure underneath, with frameworks on top, that make everything possible. Click here to try PiiX .
“We believe that all future applications should be collaborative – including apps for productivity, social collaboration, telemedicine, sports, interactive marketing, AR/VR, SaaS, gaming, you name it,” says David A. Smith , Founder & CTO of Croquet. “With this launch, Croquet is delivering all of the tools and infrastructure developers need to easily build mind-blowing, real-time, fully synchronous collaborative apps that make today’s multi-user apps look like anachronisms. We expect that developers will find amazing ways to use this technology that we haven’t even imagined yet.”
Croquet was funded in early 2020 to pursue development and private beta testing of the infrastructure, libraries, tools and reference app launched today. Use cases for the technology are vast and varied across startups, the enterprise, commercial applications, social collaboration, media, marketing, interactive advertising and social games. See more use case detail on the Croquet website.
A Peek Under the Hood
Croquet’s first-of-its-kind Edge Collaboration infrastructure is deployed globally today on every continent (except Antarctica). It provides a super-fast reflector-based network (with latency as low as 10-15ms, depending on location), as well as a unique edge collaboration protocol and synchronization service that enable real-time collaboration at the edge of the network where performance is best. Servers have long stood between users and real-time collaboration. With Edge Collaboration, nothing runs on servers so developers are free to easily create apps for instantaneous shared experiences.
All the “smarts” of the application are on the client side. Each user is operating a shared virtual machine, with everyone’s device guaranteed to run the exact same program at exactly the same time, in exactly the same way. These client-side, bit-identical virtual machines use a replicated computation model that enables ultra-low latency, low bandwidth synchronization and instantaneous interactions.
Applications generate events which are sent to an Edge Reflector, the architectural center of the Croquet infrastructure, which then redistributes it to each session participant’s replicated virtual machine, providing precise synchronization with exceedingly low latency. Reflectors are small pieces of software that sit on the Edge and are spun up or down as needed anywhere in the world to support high performance sessions. Croquet Infrastructure is highly scalable with reflectors running across the globe, all designed to work with existing online and mobile networks, including 5G. Developers can sign up here to receive a free key allowing them to start using Croquet.
“Croquet is the best thing I’ve seen in computing over the last 15 years,” says Alan Kay, an advisor to Croquet since its inception, and Turing Award Winner long considered Father of the Personal Computer. “It solves massive problems associated with building real-time collaborative applications in extremely elegant ways. The Internet has been needing this for many years.”
Other key facts about the Croquet Library , API and frameworks include:
- No back-end code; simple front-end, client-side only. Easy for even novice programmers
- Fast and simple to implement. Changes the entire multi-user app development dynamic so developers can build and deploy multi-user apps in days, not months
- Application state is automatically shared so new users can join a live session instantly
- Abstracts the developer from powerful underlying infrastructure; it just works
- Multiple frameworks available for critical tasks
- Works globally with extremely low latency
- Privacy-focused; every message is encrypted end-to-end. The servers only see encrypted data; so even leaks would do no harm to privacy
- No timing issues or out-of-order events. Croquet uses “replicated computation” to eliminate message “collisions”
- Edge reflectors exist as software and have no application state; they are extraordinarily scalable globally and can function as a self-proliferating network
- View this technical FAQ on the Croquet website
Development of the company’s current technology was led by Smith and co-founders Vanessa Freudenberg, Aran Lunzer, Yoshiki Ohshima and Brian Upton – a team of architects and engineers in Los Angeles, CA.
“This is an amazing team that has built something remarkable,” says John Payne, CEO of Croquet. “The Croquet Platform and Infrastructure will enable a whole new breed of applications that couldn’t exist before while supporting the addition of collaboration features to existing applications around the world in a highly scalable way.”
The market for collaboration technology as a whole is massive. COVID has accelerated demand by 10 years, but so far the technology has lagged. Croquet changes the conversation, enabling a huge leap forward in developing Instantaneous Shared Experiences.
About Croquet
Croquet Corporation – the technology leader in Edge Collaboration, a new, rapidly-growing sector of Edge Computing – operates a global Edge Collaboration Platform and Collaboration Infrastructure that enables developers to quickly and easily create a vast range of multi-user collaboration apps for web and mobile, at virtually limitless scale. Croquet has its spiritual roots in work begun in the 1990’s by Founder & CTO David A. Smith , Alan Kay , David P. Reed and Andreas Raab in the Croquet Project , an open source 2D/3D environment for collaborative work written in Smalltalk. Croquet was formed in 2019 and funded by SIP Global Partners and a group of experienced technology and financial industry veterans. Visit www.croquet.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
